Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988890 | 0.90 | ADORA3 (0.41) | ADORA3ADORA2AADORA1 | |
| SCHEMBL13898193 | 0.84 | ADORA3 (0.62) | ADORA3ADORA2AADORA1 | |
| SCHEMBL17706392 | 0.82 | ADORA3 (0.65) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6826487 | 0.78 | TYMP (0.37) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6824225 | 0.76 | TYMP (0.37) | ADORA3ADORA2AADORA1 | |
| SCHEMBL25605576 | 0.75 | ADORA3 (0.55) | ADORA3ADORA2AADORA1 | |
| SCHEMBL28827066 | 0.75 | ADORA3 (0.52) | ADORA3ADORA2AADORA1 | |
| SCHEMBL26128153 | 0.72 | ADORA3 (0.48) | ADORA3ADORA2AADORA1 | |
| SCHEMBL26128147 | 0.72 | ADORA3 (0.48) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6908910 | 0.71 | P2RY12 (0.59) | ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777024-B2 | Process for preparing a pentopyranosyl nucleic acid conjugate | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20090221793-A1 | PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE | SANOFI-AVENTIS S.A. (FR) | 2009-09-03 | — | — | US | disclosed |
| US-7501506-B2 | Pentopyranosyl nucleic acid conjugates | NANOGEN RECOGNOMICS GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| US-7153955-B2 | Pentopyranosyl nucleic acid arrays, and uses thereof | NANOGEN RECOGNOMICS GMBH (DE) | 2006-12-26 | — | — | US | disclosed |
| US-20060270840-A1 | Pentopyranosyl nucleic acid conjugates | SANOFI-AVENTIS S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| US-20050053945-A1 | Process for the preparation of a pentopyranosyl conjugate | NANOGEN RECOGNOMICS GMBH | 2005-03-10 | — | — | US | disclosed |
| US-20040198966-A1 | Pentopyranosylnucleoside, its preparation and use | NANOGEN RECOGNOMICS GMBH | 2004-10-07 | — | — | US | disclosed |
| EP-1017703-B1 | PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | NANOGEN RECOGNOMICS GMBH (DE) | 2004-04-28 | — | — | EP | disclosed |
| EP-1017704-B1 | USE OF A PENTOPYRANOSYL NUCLEOSIDE CONTAINING CONJUGATE FOR PRODUCING AN ARRAY | NANOGEN RECOGNOMICS GMBH (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6613894-B1 | Bonding the nucleoside to a solid support, deprotecting using an acid, reacting with a nucleoside phosphoramidite; oxidizing and coupling a biomolecule to the product | NANOGEN RECOGNOMICS GMBH (DE) | 2003-09-02 | — | — | US | disclosed |
| US-6608186-B1 | Of given formula; use for the production of a therapeutic, diagnostic and/or electronic component; use in the construction of supramolecular units | NANOGEN RECOGNOMICS GMBH (DE) | 2003-08-19 | — | — | US | disclosed |
| US-20030039997-A1 | Pentopyranosyl nucleic acid arrays, and uses thereof | AVENTIS RESEARCH AND TECHNOLOGIES GMBH & CO. KG (DE) | 2003-02-27 | — | — | US | disclosed |
| EP-1019423-B1 | METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE | NANOGEN RECOGNOMICS GMBH (DE) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221793-A1 | PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE | RNGTT, NT5C3B, FUT6 | ADORA3 679/4885ADORA2A 1033/4885ADORA1 1316/4885 |
| US-20040198966-A1 | Pentopyranosylnucleoside, its preparation and use | FUT6, ST3GAL3, FUT5 | ADORA3 1415/4885ADORA2A 1693/4885ADORA1 817/4885 |
| US-20050053945-A1 | Process for the preparation of a pentopyranosyl conjugate | FUT6, FUT5, FUCA2 | ADORA3 1529/4885ADORA2A 1972/4885ADORA1 1828/4885 |
| US-20060270840-A1 | Pentopyranosyl nucleic acid conjugates | FUT6, RNGTT, B3GAT3 | ADORA3 440/4885ADORA2A 789/4885ADORA1 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.